Regeneron Antibody for Cat Allergies Met Endpoint in Phase 2

Regeneron’s antibody cocktail to treat cat-allergic patients with asthma met its primary endpoint in a Phase 2 study.

The investigational antibody prevented early asthma reactions and met key secondary endpoints by improving lung function and increasing the amount of cat allergen that the patients could tolerate following a single dose of the treatment.

To view the source of this information click here

©2021 Bloomberg L.P.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.